Abstract:Ethnopharmacological relevance: As a classic traditional Chinese medicine, Magnolia officinalis (M. officinalis) is widely used in digestive diseases. It has rich gastrointestinal activity including inflammatory bowel disease (IBD) treatment, but the mechanism is not clear. Aim of the study: In recent years, there has been a growing interest in investigating the regulatory effects of herbal compounds on transient receptor potential (TRP) channel proteins. Transient receptor potential vanilloid 4 (TRPV4), a subtype involved in endothelial permeability regulation, was discussed as the target of M. officinalis in the treatment of IBD in the study. Based on the targeting effect of TRPV4, this study investigated the active ingredients and mechanism of M. officinalis extract in treating IBD. Materials and methods: To reveal the connection between the active ingredients in M. officinalis and TRPV4, a bioactivity-guided high performance liquid chromatography system coupled with mass spectrometry identification was utilized to screen for TRPV4 antagonists. TRPV4 siRNA knockdown experiment was employed to validate the significance of TRPV4 as a crucial target in regulating endothelial permeability by honokiol (HON). The interaction of the active ingredient representing HON with TRPV4 was confirmed by molecular docking, fluorescence-based thermal shift and live cell calcium imaging experiments. The potential binding sites and inhibitory mechanisms of HON in TRPV4 were analyzed by molecular dynamics simulation and microscale thermophoresis. The therapeutic effect of HON based on TRPV4 was discussed in DSS-IBD mice. Results: Our finding elucidated that the inhibitory activity of M. officinalis against TRPV4 is primarily attributed to HON analogues. The knockdown of TRPV4 expression significantly impaired the calcium regulation and permeability protection in endothelial cells. The mechanism study revealed that HON specifically targets the Q239 residue located in the ankyrin repeat domain of TRPV4, and competitively inhibits channel opening with adenosine triphosphate (ATP) binding. The immunofluorescence assay demonstrated that the administration of HON enhances the expression and location of VE-Cadherin to protect the endothelial barrier and attenuates immune cell infiltration. Conclusions: The finding suggested that HON alleviates IBD by improving endothelial permeability through TRPV4. The discovery provides valuable insights into the potential therapeutic strategy of active natural products for alleviating IBD.

Honokiol Up-Regulates Prostacyclin Synthease Protein Expression and Inhibits Endothelial Cell Apoptosis.

Honokiol inhibits carotid artery atherosclerotic plaque formation by suppressing inflammation and oxidative stress

Honokiol: an effective inhibitor of tumor necrosis factor-α-induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts

Honokiol Inhibits Arterial Thrombosis Through Endothelial Cell Protection and Stimulation of Prostacyclin

Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: Functional ex vivo and in vivo studies

Honokiol: an Effective Inhibitor of High-Glucose-Induced Upregulation of Inflammatory Cytokine Production in Human Renal Mesangial Cells

Inhibitory Effects of Honokiol on Lipopolysaccharide-Induced Cellular Responses and Signaling Events in Human Renal Mesangial Cells

Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IκB/NF-κB, in atherosclerotic cell model

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway

Protective effects of honokiol against oxidative stress-induced apoptotic signaling in mouse podocytes treated with H2O2.

Mechanisms Underlying the Antiapoptotic and Anti-Inflammatory Effects of Monotropein in Hydrogen Peroxide-Treated Osteoblasts.

Honokiol Inhibits the Inflammatory Reaction During Cerebral Ischemia Reperfusion by Suppressing NF-κB Activation and Cytokine Production of Glial Cells.

Hinokitiol is a novel glycoprotein VI antagonist on human platelets

Honokiol Alleviates the Degeneration of Intervertebral Disc Via Suppressing the Activation of TXNIP-NLRP3 Inflammasome Signal Pathway.

Local Honokiol Application Inhibits Intimal Thickening in Rabbits Following Carotid Artery Balloon Injury

Honokiol Alleviates Ulcerative Colitis by Targeting PPAR-γ–TLR4–NF-κB Signaling and Suppressing Gasdermin-D-mediated Pyroptosis in Vivo and in Vitro

Honokiol targeting ankyrin repeat domain of TRPV4 ameliorates endothelial permeability in mice inflammatory bowel disease induced by DSS

Structural Modification of Honokiol, A Biphenyl Occurring in Magnolia Officinalis: the Evaluation of Honokiol Analogues As Inhibitors of Angiogenesis and for Their Cytotoxicity and Structure-Activity Relationship

Honokiol: A naturally occurring lignan with pleiotropic bioactivities

Honokiol-mesoporous Silica Nanoparticles Inhibit Vascular Restenosis Via the Suppression of TGF-β Signaling Pathway.